NCT06444256View on ClinicalTrials.gov

Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

January 30, 2027

Study Completion Date

January 30, 2027

Conditions
Stimulant Use Disorder
Interventions
DRUG

SUVO

Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11

DRUG

TAU

Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.

Trial Locations (1)

77030

RECRUITING

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER